



## 期刊导读

9卷11期 2015年6月 [最新]



期刊存档

期刊存档

[查看目录](#)

## 期刊订阅



在线订阅



邮件订阅



RSS

## 作者中心



资质及晋升信息



作者查稿



写作技巧



投稿方式



作者指南

## 编委会

## 期刊服务



建议我们



会员服务



广告合作



继续教育

您的位置: [首页](#)>> 文章摘要

[中文](#) [English](#)

## 玻璃体注射抗VEGF药物与持续性眼压升高相关性的Meta分析

赵宏伟, 胡莲娜, 罗灵, 刘怡, 聂闯, 马化文

100101 北京, 解放军第306医院眼科

罗灵, Email: ling.luoling1208@gmail.com

国家自然科学基金 (81271016)

**摘要:**目的 系统评价玻璃体注射抗VEGF药物后持续性眼压升高情况。方法 计算机检索Pubmed数据库、生物医学文献数据库、中文科技期刊全文数据库, 纳入玻璃体注射抗VEGF药物发生持续性眼压升高评价者独立选择试验研究、提取资料和方法学质量评估。研究数据的统计学分析采用RevMan 5.0。纳入9篇临床研究, 其中5篇文献指出了抗VEGF药物的眼内注射与术后眼内压持续性升高相关, 4篇文献指出抗VEGF药物的眼内注射与术后眼内压持续性升高无关, 这4篇文献中其中3篇有对照组统计分析, MINORS平均得分为22.7(22~24), 其他6篇MINORS平均得分为13)。对有对照组统计分析的3篇研究进行资料合并后进行了Meta分析显示: 抗VEGF药物注射与持续性眼压升高(P=0.55)。结论 抗VEGF药物的眼内注射与术后眼内压持续性升高无必然联系。

**关键词:**眼内压; Meta分析; 玻璃体注射; 抗血管内皮生长因子

[评论](#) [收藏](#) [全文](#)

文献标引: 赵宏伟, 胡莲娜, 罗灵, 刘怡, 聂闯, 马化文. 玻璃体注射抗VEGF药物与持续性眼压升高相关性分析. 中华临床医师杂志: 电子版, 2014, 8(21): 3857-3862. [复制](#)

## 参考文献:

- [1] Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized development and validation of a new instrument[J]. ANZ J Surg, 2003, 73(9): 712-716.
- [2] 曾宪涛, 冷卫东, 李胜, 等. 如何正确理解及使用GRADE系统[J]. 中国循证医学杂志, 2010, 10(9): 990.
- [3] Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol, 2008, 246(7): 955-958.
- [4] Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy[J]. Retina, 2012, 32(1): 179-187.
- [5] Hoang QV, Mendonca LS, Delia Torre KE, et al. Effect on intraocular pressure of receiving unilateral intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol, 2012, 119(2): 321-326.

- [6] Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure increase in glaucoma patients treated with intravitreal injection of bevacizumab and ranibizumab[J]. *Retina*, 2011, 31(10): 1295-1301.
- [7] Pershing S, Bakri SJ, Moshfeghi DM, et al. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents[J]. *Surg Lasers Imaging Retina*, 2013, 44(5): 460-464.
- [8] Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressure after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib[J]. *Retina*, 2011, 31(10): 1875-1880.
- [9] Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure after intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration[J]. *J Glaucoma*, 2012, 21: 241-247.
- [10] Yu AL, Seidensticker F, Schaumberger M, et al. Evaluation of intraocular pressure changes after multiple injections of intravitreal ranibizumab[J]. *Clin Ophthalmol*, 2014, 11(10): 1753-1758.
- [11] Good TJ, Kimura AB, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents[J]. *Br J Ophthalmol*, 2011, 95(8): 1111-1115.
- [12] Kim YJ, Sung KR, Lee KS, et al. Long-Term Effects of Multiple Intravitreal Anti-vascular Endothelial Growth Factor Injections on Intraocular Pressure[J]. *Am J Ophthalmol*, 2012, 154(10): 1271-1276.
- [13] Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis[J]. *PLoS One*, 2013, 8(7): 1375-1392.
- [14] Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic and pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials[J]. *Ophthalmology*, 2012, 119(6): 1278-1282.
- [15] Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for choroidal neovascularization secondary to branch retinal vein occlusion[J]. *Cochrane Database Syst Rev*, 2013, 31(12): CD007419.
- [16] Virgili G, Parravano M, Menchini F, et al. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema[J]. *Cochrane Database Syst Rev*, 2012, 12: CD007419.
- [17] Kahook MY, Liu L, Ruzycski P, et al. High-molecular-weight aggregates in retinal neovascularization[J]. *Retina*, 2010, 30(6): 887-892.
- [18] Kim JE, Mantravadi AV, Hur EY, et al. Short-term intraocular pressure changes after intravitreal injections of anti-vascular endothelial growth factor agents[J]. *Am J Ophthalmol*, 2011, 146(6): 930-934.
- [19] Güler M, Capk?n M, Sim?ek A, et al. Short-term Effects of Intravitreal Bevacizumab on Intraocular Pressure and Anterior Chamber[J]. *Curr Eye Res*, 2014.
- [20] Carnota-Méndez P, Méndez-Vázquez C, Otero-Villar J, et al. Effect of prophylactic intravitreal injection of bevacizumab on intraocular pressure in glaucoma patients[J]. *Retina*, 2011, 31(10): 1295-1301.

and influence of vitreous reflux in pressure rise after intravitreal injections of a  
Eur J Ophthalmol, 2014, 24(5):771-777.

[21] Chehab H, Le Corre A, Giraud JM, et al. Efficacy of prophylactic treatment of  
pressure spikes due to intravitreal injections[J]. J Fr Ophtalmol, 2012, 35(8): 614-

[22] Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure  
medication on intraocular pressure spikes after intravitreal injections[J]. Arch Oph  
(12): 1523-1527.

[23] Bushtey DM, Parmley VC, Paglen P. Visual field defect associ- ated with las  
keratomileusis[J]. Am J Ophthalmol, 2000, 129(5): 668-671.

[24] Perkumas KM, Stamer WD. Protein markers and differentiation in culture for  
endothelial cells[J]. Exp Eye Res, 2012, 96(1): 82-87.

[25] Paylakhi SH, Yazdani S, April C, et al. Non-housekeeping genes expressed in  
meshwork cell cultures[J]. Mol Vis, 2012, 18: 241-254.

[26] Shin JW, Huggenberger R, Detmar M. Transcription a! profiling of VEGF-A and  
in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator  
lymphangiogenesis[J]. Blood, 2008, 12(6): 2318-2326.

[27] Singh D. Conjunctival lymphatic system[J]. J Cataract Refract Surg, 2003, 2

[编委会](#) [联系我们](#) [合作伙伴](#) [友情链接](#)

© 2015版权声明 中华临床医师杂志(电子版)编辑部  
网站建设: 北京华夏世通信息技术有限公司 京ICP备0  
北京市公安局西城分局备案编号: 110102000676